Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 3

The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis

Authors Claudia Jenneck, Natalija Novak

Published 15 July 2007 Volume 2007:3(3) Pages 411—420

Claudia Jenneck, Natalija Novak

Department of Dermatology, University of Bonn, Germany

Abstract: Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells. In addition, alefacept induces apoptosis of activated memory T cells. This paper presents an overview about the clinical studies on alefacept, its mechanism of action, and the results of the clinical trials focused on efficacy and safety of alefacept in different populations. Further on, data available on the use of alefacept in combination with other therapeutic agents are discussed.

Keywords: Alefacept, biologicals, efficacy, safety, tolerability

Download Article [PDF] 

Readers of this article also read:

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

The use of antithrombotics in patients presenting with stroke and atrial fibrillation

Carl Burgess, Tristram Ingham, Martin Woodbridge, Mark Weatherall, Michael Nowitz

Therapeutics and Clinical Risk Management 2007, 3:491-498

Published Date: 15 July 2007

A review of rabeprazole in the treatment of acid-related diseases

Fabio Pace, Stefano Pallotta, Stefania Casalini, Gabriele Bianchi Porro

Therapeutics and Clinical Risk Management 2007, 3:363-379

Published Date: 15 July 2007

Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B

Eugene B Kern, David Sherris, Angelos M Stergiou, Laura M Katz, Lisa C Rosenblatt, Jens Ponikau

Therapeutics and Clinical Risk Management 2007, 3:319-325

Published Date: 15 May 2007

Restless leg syndrome: is it a real problem?

Paul E Cotter, Shaun T O’Keeffe

Therapeutics and Clinical Risk Management 2006, 2:465-475

Published Date: 15 December 2006

House dust mite control measures in the treatment of asthma

Gillian Vallance, Charles McSharry, Stuart Wood, Neil C Thomson

Therapeutics and Clinical Risk Management 2006, 2:347-354

Published Date: 15 December 2006